Claire Mazumdar Sells 1,786 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 1,786 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $18.74, for a total value of $33,469.64. Following the transaction, the chief executive officer directly owned 339,392 shares in the company, valued at $6,360,206.08. This trade represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Claire Mazumdar also recently made the following trade(s):

• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total transaction of $49,278.63.

Bicara Therapeutics Stock Down 0.2%

BCAX opened at $18.47 on Friday. The firm’s 50 day moving average is $16.47 and its 200-day moving average is $15.78. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $19.71. The firm has a market capitalization of $1.01 billion, a P/E ratio of -8.25 and a beta of -0.78.

Key Stories Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors have recently modified their holdings of BCAX. Legal & General Group Plc lifted its position in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after buying an additional 1,474 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Bicara Therapeutics during the fourth quarter valued at approximately $45,000. Finally, Larson Financial Group LLC raised its stake in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after buying an additional 3,595 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Citigroup started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They issued an “outperform” rating for the company. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Finally, Citizens Jmp initiated coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued a “market perform” rating and a $31.00 price target for the company. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.